These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 22212583)
21. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956 [TBL] [Abstract][Full Text] [Related]
22. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Pascale A; Serfaty L J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419 [TBL] [Abstract][Full Text] [Related]
23. Telaprevir for chronic hepatitis C virus infection. Jesudian AB; Jacobson IM Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282 [TBL] [Abstract][Full Text] [Related]
24. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Hézode C Liver Int; 2012 Feb; 32 Suppl 1():32-8. PubMed ID: 22212569 [TBL] [Abstract][Full Text] [Related]
25. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy. Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330 [TBL] [Abstract][Full Text] [Related]
26. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Beste LA; Green PK; Ioannou GN Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739 [TBL] [Abstract][Full Text] [Related]
27. Telaprevir for previously treated chronic HCV infection. McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM; N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? Nicolini LA; Menzaghi B; Ricci E; Martinelli C; Magni C; Maggi P; Celesia BM; Parruti G; Babudieri S; Bonfanti P; Falasca K; Vichi F; De Socio GV; Salomoni E; Di Biagio A; Quirino T Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):37-41. PubMed ID: 26460621 [TBL] [Abstract][Full Text] [Related]
29. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Sitole M; Silva M; Spooner L; Comee MK; Malloy M Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719 [TBL] [Abstract][Full Text] [Related]
31. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Bhagani S Curr Opin HIV AIDS; 2011 Nov; 6(6):483-90. PubMed ID: 22001893 [TBL] [Abstract][Full Text] [Related]
32. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745 [TBL] [Abstract][Full Text] [Related]
33. Optimal treatment with boceprevir for chronic HCV infection. Maasoumy B; Manns MP Liver Int; 2013 Feb; 33 Suppl 1():14-22. PubMed ID: 23286841 [TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594 [TBL] [Abstract][Full Text] [Related]
35. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D; Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873 [TBL] [Abstract][Full Text] [Related]
36. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. Bräu N J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419 [TBL] [Abstract][Full Text] [Related]
37. Current management of hepatitis C virus infection in patients with HIV co-infection. Sulkowski MS J Infect Dis; 2013 Mar; 207 Suppl 1(Suppl 1):S26-32. PubMed ID: 23390302 [TBL] [Abstract][Full Text] [Related]
38. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Asselah T; Marcellin P Liver Int; 2012 Feb; 32 Suppl 1():88-102. PubMed ID: 22212578 [TBL] [Abstract][Full Text] [Related]
39. Telaprevir for previously untreated chronic hepatitis C virus infection. Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S; N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307 [TBL] [Abstract][Full Text] [Related]
40. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Marks KM; Jacobson IM Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]